As of November 14, 2026, Camp4 Therapeutics Corp has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 24, 2026 (Form 8-K, March 24, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Camp4 Therapeutics Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Camp4 Therapeutics Corp reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-24. Every row below is cited to the filing it comes from, and this page adds each new change as Camp4 Therapeutics Corp files it.
Also on the record for Camp4 Therapeutics Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 13, 2026 | Stake report, Schedule 13G/A, by Coastlands Capital LP | 9.99% of the class | 5%+ stakes | Source |
| November 12, 2026 | Stake report, Schedule 13G, by Adage Capital Management, L.P. | 6.68% of the class | 5%+ stakes | Source |
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 7.8% of the class | 5%+ stakes | Source |
| August 31, 2026 | Stake report, Schedule 13D/A, by 5AM Ventures VI, L.P. | 9.9% of the class | 5%+ stakes | Source |
| August 19, 2026 | Stake report, Schedule 13D/A, by Polaris Management Co. VII, L.L.C. | 6.3% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by BALYASNY ASSET MANAGEMENT L.P. | 4.99% of the class | 5%+ stakes | Source |
| August 10, 2026 | Stake report, Schedule 13G, by Trails Edge Capital Partners, LP | 6% of the class | 5%+ stakes | Source |
| August 5, 2026 | Stake report, Schedule 13D/A, by 5AM Ventures VI, L.P. | 9.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Balyasny Asset Management L.P. | 5.07% of the class | 5%+ stakes | Source |
| March 11, 2026 | Stake report, Schedule 13D/A, by Enavate Sciences GP, LLC | 4.8% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Vivo Opportunity Fund Holdings, L.P. | 7.4% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 9.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Camp4 Therapeutics Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on Camp4 Therapeutics Corp and the records around it.
Camp4 Therapeutics Corp elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- AH Bio Fund I, L.P. also filed stake reports on 1 other company: Freenome, Inc. (Jul 2026)
- 5AM Ventures VI, L.P. also filed stake reports on 2 other companies: ARTIVA BIOTHERAPEUTICS, INC. (Aug 2026), VOR BIOPHARMA INC. (Jul 2025)
- Enavate Sciences GP, LLC also filed stake reports on 2 other companies: Zenas BioPharma, Inc. (Aug 2026)
Watch Camp4 Therapeutics Corp
Get an email when Camp4 Therapeutics Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Camp4 Therapeutics Corp?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Camp4 Therapeutics Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Camp4 Therapeutics Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 29 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-24 | Reported | not named in the filing | 8-K, 2026-03-24 |
New leaders reset buying decisions — get the Full Report on Camp4 Therapeutics Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Camp4 Therapeutics Corp, with the record behind each one.
Find candidates like senior executive at Camp4 Therapeutics CorpEvery change, in the filing's words
Reported
On March 18, 2026, the Board of Directors (the " Board ") of the CAMP4 Therapeutics Corporation (the " Company ") appointed Michael MacLean as a Class III director, effective April 1, 2026 (the " Appointment Date ").
- Mr. MacLean has also been appointed to the Audit Committee and Compensation Committee of the Board, effective on the Appointment Date.
- In connection with this director appointment, the Board increased the size of the Board from eight members to nine members.
- Mr. MacLean, age 60, has over 35 years of financial leadership experience in the biotechnology and life sciences industries, with extensive expertise in public company reporting, capital markets transactions, internal controls, and corporate governance.
- He most recently served as Chief Financial Officer of Avidity Biosciences, Inc., a publicly traded company, until its acquisition by Novartis, a position he held from May 2020 through April 2026.
- Mr. MacLean joined Avidity prior to its initial public offering and was responsible for its finance and business functions through its initial public offering and subsequent growth as a multinational organization.
- He also served as a principal negotiator in connection with the company's acquisition by Novartis and a multi-target cardiology collaboration with Bristol Myers Squibb.
- Previously, Mr. MacLean served as Chief Financial Officer of Akcea Therapeutics, Inc. from 2017 to 2020 and as Chief Financial Officer of PureTech Health plc from 2015 to 2017.
Tools for this story
Each opens in a new tab, filled in for Camp4 Therapeutics Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
